AMANDA HILL: Open Payments
NPI 1194248179 · EUGENE, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 49 payments from 12 companies in 2025. Trend: 2023 $784 · 2024 $843 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $192 |
| Regeneron Healthcare Solutions, Inc. | 5 | $145 |
| ABBVIE INC. | 7 | $127 |
| Gilead Sciences, Inc. | 6 | $111 |
| Phathom Pharmaceuticals, Inc. | 6 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Celltrion USA Inc. | 3 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Intercept Pharmaceuticals, Inc. | 3 | $54 |
| GENZYME CORPORATION | 2 | $51 |
Products named: DUPIXENT, TREMFYA, VOQUEZNA, ENTYVIO, MAVYRET, VEGZELMA, ZENPEP, OCALIVA.
Industry payments across OR — which companies pay providers there.
